entertainment -WSS

entertainment

author：hotspot 2025-08-06 05:21:53 - browse：86967

Fatty liver foregrounds arteries and veins surrounded by red blood cells — health coverage from STAT — Adobe

As drugmakers race to join the obesity drug market ignited by the approval of Wegovy and Zepbound, they’re not just competing on their drugs’ weight loss effects. They’re also competing on their products’ ability to treat a severe form of liver disease.

A new update of the STAT Obesity Drug Tracker shows that at least 23 — about one-fifth — of the 105 obesity treatments in development or on the market are also being investigated for metabolic dysfunction-associated steatohepatitis, the fatty liver disease known as MASH (and previously called NASH).

In this update, STAT has added a category — “other diseases investigated” — to show conditions beyond obesity for which a compound is being studied. Type 2 diabetes is the most common – it’s long been linked to obesity, and the latest GLP-1 treatments like Wegovy and Zepbound were initially developed as diabetes drugs. But behind diabetes, the next most common disease under investigation for obesity candidates is MASH.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： High breast density mammograms need follow

hotspot

WSS

Dana Farber says 6 studies to be retracted and 31 corrected

To bolster infectious disease surveillance, genomics powerhouses team up

FDA greenlights medical device to combat bladder issues

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

National associations that represent hospice owe an apology

FDA sets aggressive timeline for overhauling inspection procedures

explore

entertainment

entertainment

The cancer drug shortage isn’t new — and neither are the solutions

Can U.S. cancer drug shortages be fixed?

Medical leaders decry Supreme Court decision on affirmative action

Former Pear Therapeutics executives start new VC firm

Medicare details structure of new drug price negotiation program

Republicans love RFK Jr. What's that tell us about health in 2024?

Hollywood unions extend contract negotiations for actors

FDA sets aggressive timeline for overhauling inspection procedures

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Update the Apgar Score to remove skin color

explore

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Prior authorization reform is both possible and imperative

Medicare drug price lawsuits could be good politics for Biden

TikTok, Instagram influencers need more rules for drug ads

CDC says it’s too soon to assess risk posed by Covid subvariant

How the drug

hotspot

hotspot

hotspot

knowledge